Dr. Michael Atkins, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discusses his question from ASCO 2023 regarding the long-term results of IO/TKI combinations for metastatic RCC and how its varying responses may influence debate at this year’s Uromigos: Live & Unplugged conference.
Dr. Michael Atkins on Potential RCC Debate at Uromigos: Live & Unplugged
By Michael B. Atkins, MD - Last Updated: November 6, 2023Post Tags:Uromigos Live 2023-Renal Cell Carcinoma
Related Posts
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
The panel discussed the latest updates in NMIBC, including relevant data pertaining to pembro, atezo, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.